Press releases

Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

Advicenne publishes its annual financial report

Advicenne 2017 Financial Results and Operational Perspectives for 2018

Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

Partial exercise of over – allotment option

Success of the IPO

ADV7103: 6-month data presented at ASN

Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis

Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy

Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting

Advicenne Announces the Closing of a €16 Million Financing Round

Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer

Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals

French marketing authorization approval for Levidcen

Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules